{"title": "BCG Against Covid-19 for Prevention and Milderung of Severity Trial (BAC to the PAST)", "author": "Megan Murray; MD; ScD", "url": "https://ichgcp.net/de/clinical-trials-registry/NCT04534803", "hostname": "ichgcp.net", "description": "Der Zweck dieser Studie ist es, die Wirksamkeit der Impfung gegen Bacille Calmette-Gu\u00e9rin (BCG) im Vergleich zu Placebo bei der Verringerung der schweren Covid-.... Register f\u00fcr klinische Studien. ICH GCP.", "sitename": "ichgcp.net", "date": "2020-08-21", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "BCG Against Covid-19 for Prevention and Milderung of Severity Trial (BAC to the PAST)\n[Harvard Medical School (HMS and HSDM)](https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Harvard%20Medical%20School%20%28HMS%20and%20HSDM%29)\nBacillus Calmette-Guerin gegen Covid-19 zur Vorbeugung und Linderung von Schweregradversuchen\nStudien\u00fcbersicht\nStatus\nBedingungen\nIntervention / Behandlung\nDetaillierte Beschreibung\nDies ist eine doppelblinde, randomisierte, placebokontrollierte Phase-III-Studie, die die Wirksamkeit der BCG-Impfung mit der von Placebo bei der Verringerung des Schweregrads von Covid-19 vergleicht. Die Teilnehmer m\u00fcssen die Eignungskriterien erf\u00fcllen, um in die Studie aufgenommen zu werden. Die ausgew\u00e4hlten Personen werden gebeten, eine Blut- oder Speichelprobe f\u00fcr den serologischen Covid-19-Test und einen Interferon-Gamma-Release-Assay (IGRA)-Test f\u00fcr eine Tuberkulose-Infektion bereitzustellen, nur wenn das Ergebnis eines IGRA- oder Tuberkulin-Hauttests (TST) aus dem vorherigen nicht verf\u00fcgbar ist Jahr. Die Teilnehmer werden in einer 1:1-Zuteilung randomisiert, um zu Studienbeginn eine intradermale Verabreichung einer BCG-Impfung oder eines Placebos zu erhalten. W\u00e4hrend der Nachsorge extrahiert das Studienteam die Informationen der Teilnehmer aus den Aufzeichnungen des Pflegeheims zu Covid-19-\u00e4hnlichen Symptomen, Diagnosen, Ergebnissen sowie unerw\u00fcnschten Nebenwirkungen der BCG-Impfung. Nach 6 und 12 Monaten der Nachsorge wird eine zus\u00e4tzliche Blut- oder Speichelprobe entnommen, um einen serologischen Covid-19-Test durchzuf\u00fchren.\nDie Ermittler werden 2.500 Personen untersuchen, um 2.100 Teilnehmer aufzunehmen, was dazu f\u00fchrt, dass 1.050 BCG-Impfstoff und 1.050 Placebo erhalten. Die vorgeschlagene Stichprobengr\u00f6\u00dfe f\u00fcr die Rekrutierung soll eine 80-prozentige Aussagekraft bieten, um eine 60-prozentige Wirksamkeit des Impfstoffs (ein relatives Risiko von 0,4 unter den Geimpften) mit einem Typ-1-Fehler von 0,05 in einem zweiseitigen Test zu erkennen, wobei eine Covid-19-Angriffsrate von 10 angenommen wird % bei \u00e4lteren NH und 38,5 % schweres Covid-19 bei den infizierten Patienten und ein Designeffekt = 1,2 und 15 % verloren w\u00e4hrend der 6-monatigen Nachbeobachtung. Die Anzahl der \u00fcberpr\u00fcften Personen geht davon aus, dass etwa 20 % nicht berechtigt sind/einer Registrierung nicht zustimmen.\nBeachten Sie, dass die 60 %ige Wirksamkeit des Impfstoffs auf dem beobachteten dreifachen R\u00fcckgang der Atemwegsinfektionen in der Kohorte der Jugendlichen basierte.\nZiel: Bewertung der Wirksamkeit der BCG-Impfung im Vergleich zu Placebo bei der Verringerung der schweren Covid-19-Erkrankung bei \u00e4lteren Bewohnern qualifizierter Pflegeeinrichtungen.\nPrim\u00e4rer Endpunkt 1: Als schwer eingestufte F\u00e4lle einer Covid-19-Erkrankung. Eine schwere COVID-19-Erkrankung wird definiert als: COVID-19-Erkrankung mit Krankenhausaufenthalt, Tod oder schwere Erkrankung au\u00dferhalb des Krankenhauses, wobei eine schwere Erkrankung au\u00dferhalb des Krankenhauses als Status\u00e4nderung einschlie\u00dflich Verabreichung von neuem zus\u00e4tzlichem Sauerstoff oder Abnahme der Sauerstoffs\u00e4ttigung definiert ist 10 %; Wechsel vom ambulanten zum nicht-ambulanten Status von 3+ Tagen; neue \u00c4nderung des psychischen Status, wie in der elektronischen Patientenakte dokumentiert\nDie Ermittler werden das Proportional-Hazards-Modell von Cox verwenden, um die Hazard Ratios f\u00fcr die Entwicklung von schwerem Covid-19 zwischen den BCG- und Placebo-Armen zu berechnen.\nWenn sich der BCG-Impfstoff in dieser Altersgruppe als wirksam erweist, wird er sowohl f\u00fcr die Studienteilnehmer als auch f\u00fcr andere \u00e4ltere Personen mit einem Risiko f\u00fcr eine Infektion und Erkrankung durch Covid-19 von gro\u00dfem Nutzen sein. Da derzeit keine andere Impfstoffalternative verf\u00fcgbar ist, k\u00f6nnte eine Wirksamkeit von sogar 50 % die Sterblichkeitsrate bei infizierten Patienten entsprechend senken. Es wurde berichtet, dass BCG eine Vielzahl anderer m\u00f6glicher Vorteile hat, einschlie\u00dflich einer Verringerung des Risikos einer TB-Erkrankung, der Alzheimer-Krankheit und einer Verringerung anderer Atemwegsinfektionen. Da diese Vorteile nicht in klinischen Studien nachgewiesen wurden, werden sie potenziellen Teilnehmern nicht pr\u00e4sentiert.\nStudientyp\nPhase\n- Phase 3\nTeilnahmekriterien\nZulassungskriterien\nStudienberechtigtes Alter\nAkzeptiert gesunde Freiwillige\nStudienberechtigte Geschlechter\nBeschreibung\nAufnahme:\n- Einwohner eines teilnehmenden LTCF\n- 70 Jahre oder \u00e4lter\nF\u00e4higkeit, Studienverfahren zu verstehen und mit ihnen zusammenzuarbeiten, einschlie\u00dflich der Verbandspflege.\n- Das Personal des Pflegeheims oder das Forschungsteam stellen sicher, dass die Teilnehmer die Verbandspflege korrekt durchf\u00fchren.\nAusschluss:\n- Fr\u00fchere oder aktuelle SARS-CoV2-Infektion/Covid-19-Erkrankung, definiert durch Dokumentation der Krankheit in der Krankenakte oder positivem PCR-Test.\n- Fr\u00fchere oder bekannte aktive TB-Erkrankung\n- Hat keinen etablierten Vertreter oder Vormund, hat aber eine kognitive Beeintr\u00e4chtigung, die den Teilnehmer daran hindern w\u00fcrde, das Ausma\u00df der Studienanforderungen und -risiken vollst\u00e4ndig zu verstehen, oder seine F\u00e4higkeit, eine Einverst\u00e4ndniserkl\u00e4rung abzugeben, verbietet.\n- Adipositas (Body Mass Index [BMI] > 35)\n- Fieber (>38 C) innerhalb der letzten 24 Stunden\nAktuelle oder fr\u00fchere schwerwiegende zugrunde liegende Erkrankungen:\n- HIV+\n- Geschichte der Organ- oder Knochenmarktransplantation\n- Vorgeschichte einer schweren Immunschw\u00e4chekrankheit\n- Aktive solide oder h\u00e4matologische Malignit\u00e4t, die innerhalb der letzten zwei Jahre diagnostiziert wurde\n- Vorhandensein einer signifikanten neurologischen Erkrankung, z. Alzheimer-Erkrankung\nErhalt eines der folgenden Medikamente:\nDerzeitige Einnahme von immunsuppressiven oder immunmodulatorischen Medikamenten (Inhalatoren und/oder Prednison sind akzeptabel)\n- Die \u00fcber >/= 2 Wochen verabreichten Prednison-\u00c4quivalentdosen von > 2 mg/kg oder > 20 mg Prednison pro Tag sind immunsuppressiv und sollten zusammen mit Lebendimpfstoffen vermieden werden.\n- Erwarten Sie, in den kommenden sechs Monaten eine Chemotherapie zu erhalten, in den letzten sechs Monaten eine Chemotherapie zu erhalten oder sich einer Chemotherapie zu unterziehen\n- Derzeit auf einer Anti-Zytokin-Therapie\n- Einnahme von Metformin-Behandlung\n- Verdacht auf aktive virale oder bakterielle Infektion\n- Planen Sie, das Pflegeheim innerhalb der n\u00e4chsten 6 Monate zu verlassen\n- Teilnahme an einer anderen interventionsbasierten Studie f\u00fcr Covid-19\n- Allergie gegen einen Bestandteil des BCG-Impfstoffs oder eine anaphylaktische oder allergische Reaktion auf eine fr\u00fchere Dosis der BCG-Impfung\nStudienplan\nWie ist die Studie aufgebaut?\nDesigndetails\n- Hauptzweck: VERH\u00dcTUNG\n- Zuteilung: ZUF\u00c4LLIG\n- Interventionsmodell: PARALLEL\n- Maskierung: VERDREIFACHEN\nWaffen und Interventionen\n|\n|\nTeilnehmergruppe / Arm\n|\n|\nIntervention / Behandlung\n|\n|\nEXPERIMENTAL: BCG-Impfung\nTeilnehmer, die dem BCG-Arm randomisiert wurden, erhalten einen BCG-Impfstoff. Die Impfstelle befindet sich etwa auf halber H\u00f6he der Au\u00dfenseite des Oberarms.\n|\n|\n0,1 ml rekonstituierter BCG-Impfstoff, intradermal verabreicht zu Studienbeginn.\n|\n|\nPLACEBO_COMPARATOR: Placebo-Arm\nPlacebo wird intradermal an der gleichen Stelle wie die BCG-Impfstoffe verabreicht: Oberarm.\n|\n|\n0,1 nL Verd\u00fcnnungsmittel (Kochsalzl\u00f6sung), intradermal verabreicht zu Studienbeginn\nWas misst die Studie?\nPrim\u00e4re Ergebnismessungen\n|\n|\nErgebnis Ma\u00dfnahme\n|\n|\nMa\u00dfnahmenbeschreibung\n|\n|\nZeitfenster\n|\n|\nBewertung der Wirksamkeit der BCG-Impfung im Vergleich zu Placebo bei der Verringerung der schweren Covid-19-Erkrankung bei \u00e4lteren Bewohnern qualifizierter Pflegeeinrichtungen.\nZeitfenster: 12 Monate\n|\n|\nAnzahl der Personen, bei denen eine schwere Covid-19-Erkrankung diagnostiziert wurde, wie in der elektronischen Gesundheitsakte dokumentiert; schwere Covid-19-Erkrankung ist definiert als jeder Fall von Tod, Krankenhausaufenthalt oder Nicht-Krankenhausaufenthalt, der eine erneute Verabreichung von zus\u00e4tzlichem Sauerstoff erfordert oder eine Abnahme der Sauerstoffs\u00e4ttigung um 10 % aufweist, Wechsel von ambulant zu nicht ambulant f\u00fcr 3 oder mehr Tage, oder jede neue \u00c4nderung des psychischen Gesundheitszustands.\n|\n|\n12 Monate\nSekund\u00e4re Ergebnismessungen\n|\n|\nErgebnis Ma\u00dfnahme\n|\n|\nMa\u00dfnahmenbeschreibung\n|\n|\nZeitfenster\n|\n|\nBewertung der Wirksamkeit der BCG-Impfung im Vergleich zu Placebo bei der Verringerung der folgenden Nebenwirkungen bei \u00e4lteren Bewohnern qualifizierter Pflegeeinrichtungen (nach Anzahl der F\u00e4lle):\nZeitfenster: 12 Monate\n|\n||\n|\n12 Monate\n|\n|\nBewertung der Wirksamkeit der BCG-Impfung im Vergleich zu Placebo bei der Verringerung der folgenden Nebenwirkungen bei \u00e4lteren Bewohnern qualifizierter Pflegeeinrichtungen (nach Anzahl der F\u00e4lle), Fortsetzung\nZeitfenster: 12 Monate\n|\n|\n5. Anzahl der F\u00e4lle von Einweisungen in die Intensivstation, definiert als die Anzahl der Einweisungen in die Intensivstation.\n6. Anzahl der Beatmungsf\u00e4lle mit SARS-CoV-2, definiert als die Anzahl der Teilnehmer, die eine mechanische Beatmung ben\u00f6tigen (wie von der EHR dokumentiert) und mit einem positiven SARS-CoV-2-Test verbunden sind.\n7. Anzahl der F\u00e4lle von mechanischer Beatmung, definiert als die Anzahl der Teilnehmer, die eine mechanische Beatmung ben\u00f6tigen.\n8. Anzahl der F\u00e4lle von Gesamtmortalit\u00e4t, definiert als von der Langzeitpflegeeinrichtung gemeldeter Tod.\n9. Anzahl der F\u00e4lle von Fieber oder Atemwegserkrankungen, definiert als Fieber (wie in der EHR dokumentiert) oder mindestens ein Anzeichen oder Symptom einer Atemwegserkrankung, einschlie\u00dflich Husten, Kurzatmigkeit, Atemnot/-versagen (wie in der EHR dokumentiert).\n|\n|\n12 Monate\n|\n|\nBewertung der Wirksamkeit der BCG-Impfung im Vergleich zu Placebo bei der Verringerung der folgenden Nebenwirkungen bei \u00e4lteren Bewohnern qualifizierter Pflegeeinrichtungen (nach Anzahl der Episoden):\nZeitfenster: 12 Monate\n|\n||\n|\n12 Monate\n|\n|\nBewertung der Wirksamkeit der BCG-Impfung im Vergleich zu Placebo bei der Verringerung der folgenden Nebenwirkungen bei \u00e4lteren Bewohnern qualifizierter Pflegeeinrichtungen (nach Anzahl der Tage):\nZeitfenster: 12 Monate\n|\n||\n|\n12 Monate\nMitarbeiter und Ermittler\nMitarbeiter\nErmittler\n- Hauptermittler: Megan B Murray, MD, ScD, Harvard Medical School (HMS and HSDM)\nPublikationen und hilfreiche Links\nAllgemeine Ver\u00f6ffentlichungen\n-\n[Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. No abstract available. Erratum In: Lancet Respir Med. 2020 Feb 25;:](https://pubmed.ncbi.nlm.nih.gov/32085846)\n-\n[Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.](https://ichgcp.net/de/clinical-trials-registry/publications/2554-clinical-characteristics-of-138-hospitalized-patients-with-2019-novel-coronavirus-infected-pneumonia)\n-\n[Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Apr 28;323(16):1612-1614. doi: 10.1001/jama.2020.4326.](https://ichgcp.net/de/clinical-trials-registry/publications/3644-characteristics-and-outcomes-of-21-critically-ill-patients-with-covid-19-in-washington-state)\n-\n[Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum In: JAMA Intern Med. 2020 Jul 1;180(7):1031.](https://ichgcp.net/de/clinical-trials-registry/publications/2787-risk-factors-associated-with-acute-respiratory-distress-syndrome-and-death-in-patients-with)\n-\n[Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683. No abstract available. Erratum In: JAMA. 2020 Apr 28;323(16):1619.](https://pubmed.ncbi.nlm.nih.gov/32203977)\n-\n[Alunno A, Carubbi F, Rodriguez-Carrio J. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. RMD Open. 2020 May;6(1):e001295. doi: 10.1136/rmdopen-2020-001295.](https://ichgcp.net/de/clinical-trials-registry/publications/157124-storm-typhoon-cyclone-or-hurricane-in-patients-with-covid-19-beware-of-the-same-storm-that-has-a)\n-\n[Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020 May 14;41(19):1858. doi: 10.1093/eurheartj/ehaa254. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/32227120)\n-\n[Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.](https://ichgcp.net/de/clinical-trials-registry/publications/30157-incidence-of-thrombotic-complications-in-critically-ill-icu-patients-with-covid-19)\n-\n[Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775. Erratum In: JAMA. 2020 May 26;323(20):2098.](https://ichgcp.net/de/clinical-trials-registry/publications/34355-presenting-characteristics-comorbidities-and-outcomes-among-5700-patients-hospitalized-with-covid-19)\n-\n[Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091. Erratum In: BMJ. 2020 Mar 31;368:m1295.](https://ichgcp.net/de/clinical-trials-registry/publications/26419-clinical-characteristics-of-113-deceased-patients-with-coronavirus-disease-2019-retrospective-study)\n-\n[Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, Jensen H, Sodemann M, Rodriques A, Aaby P. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol. 2005 Jun;34(3):540-7. doi: 10.1093/ije/dyh392. Epub 2005 Jan 19.](https://pubmed.ncbi.nlm.nih.gov/15659474)\n-\n[Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, Liu Q. Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):748-755. doi: 10.1093/cid/ciaa243.](https://ichgcp.net/de/clinical-trials-registry/publications/173030-clinical-features-and-short-term-outcomes-of-102-patients-with-coronavirus-disease-2019-in-wuhan)\n- Basu-Ray, I.S., M.P., Cardiac Manifestations Of Coronavirus (COVID-19), in StatPearls. 2020, StatPearls Publishing: Treasure Island (FL).\n-\n[Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.](https://ichgcp.net/de/clinical-trials-registry/publications/11474-coagulopathy-and-antiphospholipid-antibodies-in-patients-with-covid-19)\n-\n[Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. AJR Am J Roentgenol. 2020 Jul;215(1):87-93. doi: 10.2214/AJR.20.23034. Epub 2020 Mar 14.](https://pubmed.ncbi.nlm.nih.gov/32174129)\n-\n[Stam HJ, Stucki G, Bickenbach J; European Academy of Rehabilitation Medicine. Covid-19 and Post Intensive Care Syndrome: A Call for Action. J Rehabil Med. 2020 Apr 15;52(4):jrm00044. doi: 10.2340/16501977-2677.](https://ichgcp.net/de/clinical-trials-registry/publications/58845-covid-19-and-post-intensive-care-syndrome-a-call-for-action)\n- Collaborative, T.O. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv, 2020.\n- National Center for Immunization and Respiratory Diseases (NCIRD), D.o.V.D. COVID-19 in Racial and Ethnic Minority Groups. 2020.\n- Smith, K.C., I.M. Orme, and J.R. Starke, 35 - Tuberculosis vaccines, in Vaccines (Sixth Edition), S.A. Plotkin, W.A. Orenstein, and P.A. Offit, Editors. 2013, W.B. Saunders: London. p. 789-811.\n-\n[Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995 Nov 18;346(8986):1339-45. doi: 10.1016/s0140-6736(95)92348-9. No abstract available. Erratum In: Lancet 1996 Feb 3;347(8997):340.](https://pubmed.ncbi.nlm.nih.gov/7475776)\n-\n[Aaby P, Benn CS. Saving lives by training innate immunity with bacille Calmette-Guerin vaccine. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17317-8. doi: 10.1073/pnas.1215761109. Epub 2012 Oct 15. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/23071307)\n-\n[Calmette A. Preventive Vaccination Against Tuberculosis with BCG. Proc R Soc Med. 1931 Sep;24(11):1481-90. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/19988326)\n-\n[Shann F. The non-specific effects of vaccines. Arch Dis Child. 2010 Sep;95(9):662-7. doi: 10.1136/adc.2009.157537. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/20716675)\n-\n[Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther. 2013 Feb;35(2):109-14. doi: 10.1016/j.clinthera.2013.01.007. Epub 2013 Jan 31.](https://pubmed.ncbi.nlm.nih.gov/23375475)\n-\n[Higgins JP, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016 Oct 13;355:i5170. doi: 10.1136/bmj.i5170. Erratum In: BMJ. 2017 Mar 8;356:j1241.](https://ichgcp.net/de/clinical-trials-registry/publications/5364-association-of-bcg-dtp-and-measles-containing-vaccines-with-childhood-mortality-systematic-review)\n-\n[Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, Newport M, Marchant A, Aaby P. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. 2005 Jan 26;23(10):1251-7. doi: 10.1016/j.vaccine.2004.09.006.](https://pubmed.ncbi.nlm.nih.gov/15652667)\n-\n[DUBOS RJ, SCHAEDLER RW. Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections I. Protective effects. J Exp Med. 1957 Nov 1;106(5):703-17. doi: 10.1084/jem.106.5.703.](https://ichgcp.net/de/clinical-trials-registry/publications/173031-effects-of-cellular-constituents-of-mycobacteria-on-the-resistance-of-mice-to-heterologous)\n-\n[HOWARD JG, BIOZZI G, HALPERN BN, STIFFEL C, MOUTON D. The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and Salmonella enteritidis infection. Br J Exp Pathol. 1959 Jun;40(3):281-90. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/13662534)\n-\n[Sher NA, Chaparas SD, Greenberg LE, Bernard S. Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice. Infect Immun. 1975 Dec;12(6):1325-30. doi: 10.1128/iai.12.6.1325-1330.1975.](https://ichgcp.net/de/clinical-trials-registry/publications/71432-effects-of-bcg-corynebacterium-parvum-and-methanol-extration-residue-in-the-reduction-of-mortality)\n-\n[Fagelman KM, Flint LM Jr, McCoy MT, Polk HC Jr, Trachtenberg LS. Simulated surgical wound infection in mice: effect of stimulation on nonspecific host defense mechanisms. Arch Surg. 1981 Jun;116(6):761-4. doi: 10.1001/archsurg.1981.01380180021005.](https://pubmed.ncbi.nlm.nih.gov/7016070)\n-\n[Ortiz-Ortiz L, Gonzalez-Mendoza A, Lamoyi E. A vaccination procedure against Trypanosoma cruzi infection in mice by nonspecific immunization. J Immunol. 1975 Apr;114(4):1424-5. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/804010)\n-\n[Kuhn RE, Vaughn RT, Herbst GA. The effect of BCG on the course of experimental Chagas' disease in mice. Int J Parasitol. 1975 Oct;5(5):557-60. doi: 10.1016/0020-7519(75)90049-1. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/808508)\n-\n[Hoff R. Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo. J Exp Med. 1975 Aug 1;142(2):299-311. doi: 10.1084/jem.142.2.299.](https://ichgcp.net/de/clinical-trials-registry/publications/173032-killing-in-vitro-of-trypanosoma-cruzi-by-macrophages-from-mice-immunized-with-t-cruzi-or-bcg-and)\n-\n[Civil RH, Warren KS, Mahmoud AA. Conditions for bacille Calmette-Guerin-induced resistance to infection with Schistosoma mansoni in mice. J Infect Dis. 1978 May;137(5):550-5. doi: 10.1093/infdis/137.5.550.](https://pubmed.ncbi.nlm.nih.gov/659914)\n-\n[Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun. 1977 Apr;16(1):249-57. doi: 10.1128/iai.16.1.249-257.1977.](https://ichgcp.net/de/clinical-trials-registry/publications/173033-effect-of-treatment-with-bcg-on-the-course-of-visceral-leishmaniasis-in-balb-c-mice)\n-\n[Clark IA, Allison AC, Cox FE. Protection of mice against Babesia and Plasmodium with BCG. Nature. 1976 Jan 29;259(5541):309-11. doi: 10.1038/259309a0. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/765838)\n-\n[Parra M, Liu X, Derrick SC, Yang A, Tian J, Kolibab K, Kumar S, Morris SL. Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination. PLoS One. 2013 Jul 4;8(7):e66115. doi: 10.1371/journal.pone.0066115. Print 2013.](https://ichgcp.net/de/clinical-trials-registry/publications/173034-molecular-analysis-of-non-specific-protection-against-murine-malaria-induced-by-bcg-vaccination)\n-\n[van 't Wout JW, Poell R, van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol. 1992 Nov;36(5):713-9. doi: 10.1111/j.1365-3083.1992.tb03132.x.](https://pubmed.ncbi.nlm.nih.gov/1439583)\n-\n[Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42. doi: 10.1073/pnas.1202870109. Epub 2012 Sep 17.](https://ichgcp.net/de/clinical-trials-registry/publications/8304-bacille-calmette-guerin-induces-nod2-dependent-nonspecific-protection-from-reinfection-via)\n-\n[Werner GT. The effect of BCG-vaccination on vaccinia virus infections in mice. Experientia. 1979 Nov 15;35(11):1514-5. doi: 10.1007/BF01962818.](https://pubmed.ncbi.nlm.nih.gov/389657)\n-\n[Suenaga T, Okuyama T, Yoshida I, Azuma M. Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance. Infect Immun. 1978 Apr;20(1):312-4. doi: 10.1128/iai.20.1.312-314.1978.](https://ichgcp.net/de/clinical-trials-registry/publications/173035-effect-of-mycobacterium-tuberculosis-bcg-infection-on-the-resistance-of-mice-to-ectromelia-virus)\n-\n[Sakuma T, Suenaga T, Yoshida I, Azuma M. Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect Immun. 1983 Nov;42(2):567-73. doi: 10.1128/iai.42.2.567-573.1983.](https://ichgcp.net/de/clinical-trials-registry/publications/71433-mechanisms-of-enhanced-resistance-of-mycobacterium-bovis-bcg-treated-mice-to-ectromelia-virus)\n-\n[Larson CL, Ushijima RN, Karim R, Baker MB, Baker RE. Herpesvirus hominis type 2 infections in rabbits: effect of prior immunization with attenuated Mycobacterium bovis (BCG) cells. Infect Immun. 1972 Oct;6(4):465-8. doi: 10.1128/iai.6.4.465-468.1972.](https://ichgcp.net/de/clinical-trials-registry/publications/173036-herpesvirus-hominis-type-2-infections-in-rabbits-effect-of-prior-immunization-with-attenuated)\n-\n[Starr SE, Visintine AM, Tomeh MO, Nahmias AJ. Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc Soc Exp Biol Med. 1976 May;152(1):57-60. doi: 10.3181/00379727-152-39327.](https://pubmed.ncbi.nlm.nih.gov/177992)\n-\n[Floc'h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin). Ann Immunol (Paris). 1976 Mar-Apr;127(2):173-86.](https://pubmed.ncbi.nlm.nih.gov/180868)\n-\n[Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. J Infect Dis. 1977 Aug;136(2):171-5. doi: 10.1093/infdis/136.2.171.](https://pubmed.ncbi.nlm.nih.gov/894076)\n-\n[de Bree LCJ, Marijnissen RJ, Kel JM, Rosendahl Huber SK, Aaby P, Benn CS, Wijnands MVW, Diavatopoulos DA, van Crevel R, Joosten LAB, Netea MG, Dulos J. Bacillus Calmette-Guerin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice. Front Immunol. 2018 Apr 30;9:869. doi: 10.3389/fimmu.2018.00869. eCollection 2018. Erratum In: Front Immunol. 2018 Oct 25;9:2471.](https://ichgcp.net/de/clinical-trials-registry/publications/173037-bacillus-calmette-guerin-induced-trained-immunity-is-not-protective-for-experimental-influenza-a)\n-\n[Kulkarni S, Mukherjee S, Pandey A, Dahake R, Padmanabhan U, Chowdhary AS. Bacillus Calmette-Guerin Confers Neuroprotection in a Murine Model of Japanese Encephalitis. Neuroimmunomodulation. 2016;23(5-6):278-286. doi: 10.1159/000452171. Epub 2017 Feb 17.](https://pubmed.ncbi.nlm.nih.gov/28208151)\n-\n[LEMONDE P, CLODE M. Effect of BCG infection on leukemia and polyoma in mice and hamsters. Proc Soc Exp Biol Med. 1962 Dec;111:739-42. doi: 10.3181/00379727-111-27908. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/13929573)\n-\n[Houchens DP, Goldberg AI, Gaston MR, Kende M, Goldin A. Studies of the effects of Bacillus Calmette-Guerin on Moloney sarcoma virus-induced tumors in normal and immunosuppressed mice. Cancer Res. 1973 Apr;33(4):685-90. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/4696469)\n-\n[Larson CL, Baker RE, Ushijima RN, Baker MB, Gillespie C. Immunotherapy of Friend disease in mice employing viable BCG vaccine. Proc Soc Exp Biol Med. 1972 Jun;140(2):700-2. doi: 10.3181/00379727-140-36534. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/4556666)\n-\n[Niobey FM, Duchiade MP, Vasconcelos AG, de Carvalho ML, Leal Mdo C, Valente JG. [Risk factors for death caused by pneumonia in children younger than 1 year old in a metropolitan region of southeastern Brazil. A case- control study]. Rev Saude Publica. 1992 Aug;26(4):229-38. doi: 10.1590/s0034-89101992000400004. Portuguese.](https://pubmed.ncbi.nlm.nih.gov/1342506)\n-\n[Hollm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among Bacille Calmette-Guerin (BCG)-vaccinated children. Pediatrics. 2014 Jan;133(1):e73-81. doi: 10.1542/peds.2013-2218. Epub 2013 Dec 30.](https://pubmed.ncbi.nlm.nih.gov/24379224)\n-\n[de Castro MJ, Pardo-Seco J, Martinon-Torres F. Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clin Infect Dis. 2015 Jun 1;60(11):1611-9. doi: 10.1093/cid/civ144. Epub 2015 Feb 27.](https://pubmed.ncbi.nlm.nih.gov/25725054)\n-\n[Chisti MJ, Salam MA, Ahmed T, Shahid AS, Shahunja KM, Faruque AS, Bardhan PK, Hossain MI, Islam MM, Das SK, Huq S, Shahrin L, Huq E, Chowdhury F, Ashraf H. Lack of BCG vaccination and other risk factors for bacteraemia in severely malnourished children with pneumonia. Epidemiol Infect. 2015 Mar;143(4):799-803. doi: 10.1017/S0950268814001368. Epub 2014 Jun 3.](https://ichgcp.net/de/clinical-trials-registry/publications/173038-lack-of-bcg-vaccination-and-other-risk-factors-for-bacteraemia-in-severely-malnourished-children)\n-\n[Muthumbi E, Lowe BS, Muyodi C, Getambu E, Gleeson F, Scott JAG. Risk factors for community-acquired pneumonia among adults in Kenya: a case-control study. Pneumonia (Nathan). 2017 Nov 25;9:17. doi: 10.1186/s41479-017-0041-2. eCollection 2017.](https://ichgcp.net/de/clinical-trials-registry/publications/173039-risk-factors-for-community-acquired-pneumonia-among-adults-in-kenya-a-case-control-study)\n-\n[Stensballe LG, Ravn H, Birk NM, Kjaergaard J, Nissen TN, Pihl GT, Thostesen LM, Greisen G, Jeppesen DL, Kofoed PE, Pryds O, Sorup S, Aaby P, Benn CS. BCG Vaccination at Birth and Rate of Hospitalization for Infection Until 15 Months of Age in Danish Children: A Randomized Clinical Multicenter Trial. J Pediatric Infect Dis Soc. 2019 Jul 1;8(3):213-220. doi: 10.1093/jpids/piy029. Erratum In: J Pediatric Infect Dis Soc. 2020 Feb 28;9(1):106.](https://pubmed.ncbi.nlm.nih.gov/29635419)\n-\n[Haahr S, Michelsen SW, Andersson M, Bjorn-Mortensen K, Soborg B, Wohlfahrt J, Melbye M, Koch A. Non-specific effects of BCG vaccination on morbidity among children in Greenland: a population-based cohort study. Int J Epidemiol. 2016 Dec 1;45(6):2122-2130. doi: 10.1093/ije/dyw244.](https://pubmed.ncbi.nlm.nih.gov/28338723)\n-\n[Kjaergaard J, Birk NM, Nissen TN, Thostesen LM, Pihl GT, Benn CS, Jeppesen DL, Pryds O, Kofoed PE, Aaby P, Greisen G, Stensballe LG. Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. Pediatr Res. 2016 Nov;80(5):681-685. doi: 10.1038/pr.2016.142. Epub 2016 Jul 18.](https://pubmed.ncbi.nlm.nih.gov/27429204)\n-\n[Wardhana, Datau EA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011 Jul;43(3):185-90.](https://ichgcp.net/de/clinical-trials-registry/publications/5367-the-efficacy-of-bacillus-calmette-guerin-vaccinations-for-the-prevention-of-acute-upper-respiratory)\n-\n[Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.](https://ichgcp.net/de/clinical-trials-registry/publications/5366-prevention-of-m-tuberculosis-infection-with-h4-ic31-vaccine-or-bcg-revaccination)\n-\n[Anderson FD, Ushijima RN, Larson CL. Recurrent herpes genitalis. Treatment with Mycobacterium bovis (BCG). Obstet Gynecol. 1974 Jun;43(6):797-805. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/4364209)\n-\n[Hippmann G, Wekkeli M, Rosenkranz AR, Jarisch R, Gotz M. [Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination]. Wien Klin Wochenschr. 1992;104(7):200-4. German.](https://pubmed.ncbi.nlm.nih.gov/1523844)\n-\n[Douglas JM, Vontver LA, Stamm WE, Reeves WC, Critchlow C, Remington ML, Holmes KK, Corey L. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes. Antimicrob Agents Chemother. 1985 Feb;27(2):203-6. doi: 10.1128/AAC.27.2.203.](https://ichgcp.net/de/clinical-trials-registry/publications/173040-ineffectiveness-and-toxicity-of-bcg-vaccine-for-the-prevention-of-recurrent-genital-herpes)\n-\n[Podder I, Bhattacharya S, Mishra V, Sarkar TK, Chandra S, Sil A, Pal S, Kumar D, Saha A, Shome K, Bandyopadhyay D, Das NK. Immunotherapy in viral warts with intradermal Bacillus Calmette-Guerin vaccine versus intradermal tuberculin purified protein derivative: A double-blind, randomized controlled trial comparing effectiveness and safety in a tertiary care center in Eastern India. Indian J Dermatol Venereol Leprol. 2017 May-Jun;83(3):411. doi: 10.4103/0378-6323.193623.](https://ichgcp.net/de/clinical-trials-registry/publications/173041-immunotherapy-in-viral-warts-with-intradermal-bacillus-calmette-guerin-vaccine-versus-intradermal)\n-\n[Daulatabad D, Pandhi D, Singal A. BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area? Dermatol Ther. 2016 May;29(3):168-72. doi: 10.1111/dth.12336. Epub 2016 Jan 26.](https://pubmed.ncbi.nlm.nih.gov/26809285)\n-\n[Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol. 2013 Jan-Feb;30(1):60-3. doi: 10.1111/j.1525-1470.2012.01848.x. Epub 2012 Sep 7.](https://pubmed.ncbi.nlm.nih.gov/22958215)\n-\n[Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, Kumar V, Xavier RJ, Wijmenga C, Joosten LAB, Reusken CBEM, Benn CS, Aaby P, Koopmans MP, Stunnenberg HG, van Crevel R, Netea MG. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5. doi: 10.1016/j.chom.2017.12.010.](https://ichgcp.net/de/clinical-trials-registry/publications/5362-bcg-vaccination-protects-against-experimental-viral-infection-in-humans-through-the-induction-of)\n-\n[Brewer MA, Edwards KM, Palmer PS, Hinson HP. Bacille Calmette-Guerin immunization in normal healthy adults. J Infect Dis. 1994 Aug;170(2):476-9. doi: 10.1093/infdis/170.2.476.](https://pubmed.ncbi.nlm.nih.gov/8035041)\n-\n[Hoft DF, Leonardi C, Milligan T, Nahass GT, Kemp B, Cook S, Tennant J, Carey M. Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination. Clin Infect Dis. 1999 Apr;28(4):785-90. doi: 10.1086/515201.](https://pubmed.ncbi.nlm.nih.gov/10825039)\n-\n[Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J Infect Dis. 1996 Jul;174(1):113-9. doi: 10.1093/infdis/174.1.113.](https://pubmed.ncbi.nlm.nih.gov/8655980)\n-\n[Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom WA, Johnson JL. Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine. 2014 Jun 30;32(31):3982-8. doi: 10.1016/j.vaccine.2014.04.084. Epub 2014 May 9.](https://ichgcp.net/de/clinical-trials-registry/publications/5371-safety-and-reactogenicity-of-bcg-revaccination-with-isoniazid-pretreatment-in-tst-positive-adults)\n-\n[Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res. 1984;21:107-93. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/6475644)\n-\n[Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, Andrasofszky B, Lugosi L, Vadasz I, Mihailescu P, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. 1988 Jun;63(2):47-59. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/3066422)\n-\n[BCG vaccines: WHO position paper - February 2018. Wkly Epidemiol Rec. 2018 Feb 23;93(8):73-96. No abstract available. English, French.](https://pubmed.ncbi.nlm.nih.gov/29474026)\n-\n[Sakula A. BCG: who were Calmette and Guerin? Thorax. 1983 Nov;38(11):806-12. doi: 10.1136/thx.38.11.806. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/6359561)\n- Calmette, A.G., C.; Weill-Halle, B., Essai d'immunisation contre l'infection tuberculeuse. Bull Acad Med Paris, 1924(91): p. 787-796.\n-\n[Oettinger T, Jorgensen M, Ladefoged A, Haslov K, Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis. 1999;79(4):243-50. doi: 10.1054/tuld.1999.0206.](https://pubmed.ncbi.nlm.nih.gov/10692993)\n-\n[Liu J, Tran V, Leung AS, Alexander DC, Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin. 2009 Feb;5(2):70-8. doi: 10.4161/hv.5.2.7210. Epub 2009 Feb 20.](https://pubmed.ncbi.nlm.nih.gov/19164935)\n-\n[Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine. 1999 Feb 26;17(7-8):915-22. doi: 10.1016/s0264-410x(98)00277-1.](https://pubmed.ncbi.nlm.nih.gov/10067698)\n-\n[OBAYASHI Y. Dried BCG vaccine. Monogr Ser World Health Organ. 1955;(28):1-220. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/13268024)\n-\n[Lind A. The Swedish strain of BCG. Tubercle. 1983 Sep;64(3):223-4. doi: 10.1016/0041-3879(83)90019-3. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/6636307)\n- WALLGREN, A., INTRADERMAL VACCINATIONS WITH B C G VIRUS: PRELIMINARY NOTE. Journal of the American Medical Association, 1928. 91(24): p. 1876-1881.\n-\n[Chen JM, Islam ST, Ren H, Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine. 2007 Nov 23;25(48):8114-22. doi: 10.1016/j.vaccine.2007.09.041. Epub 2007 Oct 8.](https://pubmed.ncbi.nlm.nih.gov/17954004)\n-\n[Abdallah AM, Hill-Cawthorne GA, Otto TD, Coll F, Guerra-Assuncao JA, Gao G, Naeem R, Ansari H, Malas TB, Adroub SA, Verboom T, Ummels R, Zhang H, Panigrahi AK, McNerney R, Brosch R, Clark TG, Behr MA, Bitter W, Pain A. Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. Sci Rep. 2015 Oct 21;5:15443. doi: 10.1038/srep15443.](https://ichgcp.net/de/clinical-trials-registry/publications/173042-genomic-expression-catalogue-of-a-global-collection-of-bcg-vaccine-strains-show-evidence-for-highly)\n-\n[Taniguchi K, Miyatake Y, Hayashi D, Takami A, Itoh S, Yamamoto S, Hida S, Onozaki K, Takii T. Early-shared Mycobacterium bovis bacillus Calmette-Guerin sub-strains induce Th1 cytokine production in vivo. Microbiol Immunol. 2015 Nov;59(11):684-9. doi: 10.1111/1348-0421.12326.](https://ichgcp.net/de/clinical-trials-registry/publications/173043-early-shared-mycobacterium-bovis-bacillus-calmette-guerin-sub-strains-induce-th1-cytokine-production)\n-\n[Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, Robins-Browne R, Hanekom WA, Britton WJ, Curtis N. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med. 2012 Jan 15;185(2):213-22. doi: 10.1164/rccm.201104-0714OC. Epub 2011 Nov 3.](https://pubmed.ncbi.nlm.nih.gov/22071384)\n-\n[Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007 Jul;13(7):843-50. doi: 10.1038/nm1592. Epub 2007 Jun 10.](https://pubmed.ncbi.nlm.nih.gov/17558415)\n-\n[Davids V, Hanekom WA, Mansoor N, Gamieldien H, Gelderbloem SJ, Hawkridge A, Hussey GD, Hughes EJ, Soler J, Murray RA, Ress SR, Kaplan G. The effect of bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis. 2006 Feb 15;193(4):531-6. doi: 10.1086/499825. Epub 2006 Jan 13.](https://pubmed.ncbi.nlm.nih.gov/16425132)\n-\n[Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, Dos Santos S, Duthoy S, Lacroix C, Garcia-Pelayo C, Inwald JK, Golby P, Garcia JN, Hewinson RG, Behr MA, Quail MA, Churcher C, Barrell BG, Parkhill J, Cole ST. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5596-601. doi: 10.1073/pnas.0700869104. Epub 2007 Mar 19.](https://ichgcp.net/de/clinical-trials-registry/publications/173044-genome-plasticity-of-bcg-and-impact-on-vaccine-efficacy)\n-\n[Schaltz-Buchholzer F, Bjerregaard-Andersen M, Oland CB, Golding C, Stjernholm EB, Monteiro I, Aaby P, Benn CS. Early Vaccination With Bacille Calmette-Guerin-Denmark or BCG-Japan Versus BCG-Russia to Healthy Newborns in Guinea-Bissau: A Randomized Controlled Trial. Clin Infect Dis. 2020 Nov 5;71(8):1883-1893. doi: 10.1093/cid/ciz1080.](https://pubmed.ncbi.nlm.nih.gov/31677386)\n-\n[Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, Sterne JA. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014 Feb;58(4):470-80. doi: 10.1093/cid/cit790. Epub 2013 Dec 13.](https://pubmed.ncbi.nlm.nih.gov/24336911)\n-\n[Favorov M, Ali M, Tursunbayeva A, Aitmagambetova I, Kilgore P, Ismailov S, Chorba T. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guerin (BCG) vaccines from different sources, Kazakhstan. PLoS One. 2012;7(3):e32567. doi: 10.1371/journal.pone.0032567. Epub 2012 Mar 9.](https://ichgcp.net/de/clinical-trials-registry/publications/124839-comparative-tuberculosis-tb-prevention-effectiveness-in-children-of-bacillus-calmette-guerin-bcg)\n-\n[Toida I, Nakata S. [Severe adverse reactions after vaccination with Japanese BCG vaccine: a review]. Kekkaku. 2007 Nov;82(11):809-24. Japanese.](https://pubmed.ncbi.nlm.nih.gov/18078106)\n-\n[Jou R, Huang WL, Su WJ. Tokyo-172 BCG vaccination complications, Taiwan. Emerg Infect Dis. 2009 Sep;15(9):1525-6. doi: 10.3201/eid1509.081336. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/19788832)\n-\n[Hawkridge A, Hatherill M, Little F, Goetz MA, Barker L, Mahomed H, Sadoff J, Hanekom W, Geiter L, Hussey G; South African BCG trial team. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ. 2008 Nov 13;337:a2052. doi: 10.1136/bmj.a2052.](https://ichgcp.net/de/clinical-trials-registry/publications/173045-efficacy-of-percutaneous-versus-intradermal-bcg-in-the-prevention-of-tuberculosis-in-south-african)\n-\n[Guerin N, Teulieres L, Noba A, Schlumberger M, Bregere P, Chauvin P. Comparison of the safety and immunogenicity of the lyophilized Merieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal. Vaccine. 1999 Jan;17(2):105-9. doi: 10.1016/s0264-410x(98)00186-8.](https://pubmed.ncbi.nlm.nih.gov/9987142)\n-\n[Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726. doi: 10.1073/pnas.2008410117. Epub 2020 Jul 9. Erratum In: Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27741-27742.](https://ichgcp.net/de/clinical-trials-registry/publications/5373-bcg-vaccine-protection-from-severe-coronavirus-disease-2019-covid-19)\n- Gallagher, J., C. Watson, and M. Ledwidge, Association of Bacille Calmette-Gu\u00e9rin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries. medRxiv, 2020: p. 2020.06.03.20121624.\n-\n[Berg MK, Yu Q, Salvador CE, Melani I, Kitayama S. Mandated Bacillus Calmette-Guerin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Sci Adv. 2020 Aug 5;6(32):eabc1463. doi: 10.1126/sciadv.abc1463. eCollection 2020 Aug.](https://ichgcp.net/de/clinical-trials-registry/publications/173046-mandated-bacillus-calmette-guerin-bcg-vaccination-predicts-flattened-curves-for-the-spread-of-covid)\n-\n[Klinger D, Blass I, Rappoport N, Linial M. Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis. Vaccines (Basel). 2020 Jul 11;8(3):378. doi: 10.3390/vaccines8030378.](https://ichgcp.net/de/clinical-trials-registry/publications/173047-significantly-improved-covid-19-outcomes-in-countries-with-higher-bcg-vaccination-coverage-a)\n- Akiyama, Y. and T. Ishida, Relationship between COVID-19 death toll doubling time and national BCG vaccination policy. medRxiv, 2020: p. 2020.04.06.20055251.\n-\n[Sheahan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, Heise MT. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 2008 Dec;4(12):e1000240. doi: 10.1371/journal.ppat.1000240. Epub 2008 Dec 12.](https://ichgcp.net/de/clinical-trials-registry/publications/173048-myd88-is-required-for-protection-from-lethal-infection-with-a-mouse-adapted-sars-cov)\n-\n[Totura AL, Whitmore A, Agnihothram S, Schafer A, Katze MG, Heise MT, Baric RS. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. mBio. 2015 May 26;6(3):e00638-15. doi: 10.1128/mBio.00638-15.](https://ichgcp.net/de/clinical-trials-registry/publications/173049-toll-like-receptor-3-signaling-via-trif-contributes-to-a-protective-innate-immune-response-to-severe)\n-\n[Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020 Jun;20(6):375-388. doi: 10.1038/s41577-020-0285-6. Epub 2020 Mar 4.](https://ichgcp.net/de/clinical-trials-registry/publications/45303-defining-trained-immunity-and-its-role-in-health-and-disease)\n-\n[Mitroulis I, Ruppova K, Wang B, Chen LS, Grzybek M, Grinenko T, Eugster A, Troullinaki M, Palladini A, Kourtzelis I, Chatzigeorgiou A, Schlitzer A, Beyer M, Joosten LAB, Isermann B, Lesche M, Petzold A, Simons K, Henry I, Dahl A, Schultze JL, Wielockx B, Zamboni N, Mirtschink P, Coskun U, Hajishengallis G, Netea MG, Chavakis T. Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity. Cell. 2018 Jan 11;172(1-2):147-161.e12. doi: 10.1016/j.cell.2017.11.034.](https://ichgcp.net/de/clinical-trials-registry/publications/111926-modulation-of-myelopoiesis-progenitors-is-an-integral-component-of-trained-immunity)\nN\u00fctzliche Links\nStudienaufzeichnungsdaten\nHaupttermine studieren\nStudienbeginn (ERWARTET)\nPrim\u00e4rer Abschluss (ERWARTET)\nStudienabschluss (ERWARTET)\nStudienanmeldedaten\nZuerst eingereicht\nZuerst eingereicht, das die QC-Kriterien erf\u00fcllt hat\nZuerst gepostet (TATS\u00c4CHLICH)\nStudienaufzeichnungsaktualisierungen\nLetztes Update gepostet (TATS\u00c4CHLICH)\nLetztes eingereichtes Update, das die QC-Kriterien erf\u00fcllt\nZuletzt verifiziert\nMehr Informationen\nBegriffe im Zusammenhang mit dieser Studie\nZus\u00e4tzliche relevante MeSH-Bedingungen\n-\n[Coronavirus-Infektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronavirus%20Infections)\n-\n[Coronaviridae-Infektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections)\n-\n[Nidovirales-Infektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Nidovirales%20Infections)\n-\n[RNA-Virusinfektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections)\n-\n[Viruserkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Virus%20Diseases)\n-\n[Infektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Infections)\n-\n[Infektionen der Atemwege](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections)\n-\n[Erkrankungen der Atemwege](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases)\n-\n[Pneumonie, viral](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral)\n-\n[Lungenentz\u00fcndung](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pneumonia)\n-\n[Lungenkrankheit](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lung%20Diseases)\n-\n[COVID-19](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=COVID-19)\n-\n[Physiologische Wirkungen von Arzneimitteln](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs)\n-\n[Immunologische Faktoren](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Immunologic%20Factors)\n-\n[Adjuvantien, Immunologische](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Adjuvants%2C%20Immunologic)\n-\n[BCG-Impfung](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=BCG%20Vaccine)\nAndere Studien-ID-Nummern\n- IRB20-1243\nPlan f\u00fcr individuelle Teilnehmerdaten (IPD)\nPlanen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?\nArzneimittel- und Ger\u00e4teinformationen, Studienunterlagen\nStudiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt\nStudiert ein von der US-amerikanischen FDA reguliertes Ger\u00e4teprodukt\nDiese Informationen wurden ohne \u00c4nderungen direkt von der Website\n[clinicaltrials.gov](https://clinicaltrials.gov) abgerufen. Wenn Sie Ihre Studiendaten \u00e4ndern, entfernen oder aktualisieren m\u00f6chten, wenden Sie sich bitte an [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Sobald eine \u00c4nderung auf [clinicaltrials.gov](https://clinicaltrials.gov) implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .\nKlinische Studien zur Covid19\n-\nNCT06099613Rekrutierung\n-\nNCT06099795Noch keine Rekrutierung\n[Bewertung der \u00dcbereinstimmung zwischen Ausatemlufttest (eBAM-CoV) und RT-PCR zum Nachweis von SARS-CoV-2 (eBAM_CoV)](https://ichgcp.net/de/clinical-trials-registry/NCT06099795)COVID-19 | Coronavirus | SARS-CoV-2-Infektion\n-\nNCT06097403Noch keine RekrutierungCOVID-19-assoziierte Koagulopathie\n-\nNCT06097442RekrutierungPostakute Folgen einer SARS-COV-2-Infektion\n-\nNCT06096571Noch keine Rekrutierung\n-\nNCT06095258Noch keine Rekrutierung\n-\nNCT06095297Noch keine RekrutierungKognitive Beeintr\u00e4chtigung | Kognitive Dysfunktion | Lange COVID | Hirnnebel | Postakutes COVID-19-Syndrom\n-\nNCT06091280Noch keine Rekrutierung\n[Heimtrainingsprogramm f\u00fcr die Kraft der Atemmuskulatur f\u00fcr Personen mit anhaltender Dyspnoe nach COVID-19](https://ichgcp.net/de/clinical-trials-registry/NCT06091280)Dyspnoe | Post-COVID-19-Syndrom\n-\nNCT06091358Noch keine Rekrutierung\n-\nNCT06091384RekrutierungHerz-Kreislauf-Anomalien | Post-COVID-19-Syndrom | K\u00f6rperliche Bet\u00e4tigung\nKlinische Studien zur BCG-Impfung\n-\nNCT05981131Rekrutierung\n[Follow-up von intravesikalem N-803 Plus BCG bei BCG-naivem nicht-muskelinvasivem Blasenkrebs (NMIBC)](https://ichgcp.net/de/clinical-trials-registry/NCT05981131)Nicht muskelinvasiver Blasenkrebs\n-\nNCT05866536Rekrutierung\n[Wiederholte BCG-Impfungen zur Behandlung von neu auftretendem Typ-1-Diabetes bei Kindern im Alter von 8 bis 19 Jahren](https://ichgcp.net/de/clinical-trials-registry/NCT05866536)Diabetes Mellitus | Diabetes Typ 1 | Diabetes Typ1 | Autoimmundiabetes\n-\nNCT05820594Rekrutierung\n-\nNCT05766345Noch keine RekrutierungEpigenetik | Trainierte Immunit\u00e4t | BCG-Impfung\n-\nNCT05701332Noch keine RekrutierungUrothelkarzinom Blase | Spermienzahl, niedrig | Hoden; Fibrose\n-\nNCT05591339Noch keine RekrutierungDiabetes Mellitus | BCG-Impfreaktion\n-\nNCT05539989Noch keine Rekrutierung\n-\nNCT05538663RekrutierungNicht muskelinvasiver Blasenkrebs\n-\n-\nNCT05332353Rekrutierung\n[Auf maschinellem Lernen basierende Vorhersage der BCG-Reaktion bei Hochrisikopatienten mit nicht-muskelinvasivem Blasenkrebs](https://ichgcp.net/de/clinical-trials-registry/NCT05332353)Nicht muskelinvasiver Blasenkrebs", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/de", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/ich-e-group-of-guidelines", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/events", "https://ichgcp.net/de/clinical-trials-registry/publications", "https://ichgcp.net/de/clinical-trials-registry/researchers", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/clinical-trials-registry/NCT04534803", "https://telegram.me/share/url?url=https://ichgcp.net/de/clinical-trials-registry/NCT04534803&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/de/clinical-trials-registry/NCT04534803", "https://ichgcp.net/de", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Harvard%20Medical%20School%20%28HMS%20and%20HSDM%29", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Covid19", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=BCG%20Vaccine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Placebo", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=BCG%20Vaccine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Placebo", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Harvard%20Medical%20School%20%28HMS%20and%20HSDM%29", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Texas%20Medical%20Research%20Associates%2C%20L.L.C.", "https://pubmed.ncbi.nlm.nih.gov/32085846", "https://ichgcp.net/de/clinical-trials-registry/publications/2554-clinical-characteristics-of-138-hospitalized-patients-with-2019-novel-coronavirus-infected-pneumonia", "https://ichgcp.net/de/clinical-trials-registry/publications/3644-characteristics-and-outcomes-of-21-critically-ill-patients-with-covid-19-in-washington-state", "https://ichgcp.net/de/clinical-trials-registry/publications/2787-risk-factors-associated-with-acute-respiratory-distress-syndrome-and-death-in-patients-with", "https://pubmed.ncbi.nlm.nih.gov/32203977", "https://ichgcp.net/de/clinical-trials-registry/publications/157124-storm-typhoon-cyclone-or-hurricane-in-patients-with-covid-19-beware-of-the-same-storm-that-has-a", "https://pubmed.ncbi.nlm.nih.gov/32227120", "https://ichgcp.net/de/clinical-trials-registry/publications/30157-incidence-of-thrombotic-complications-in-critically-ill-icu-patients-with-covid-19", "https://ichgcp.net/de/clinical-trials-registry/publications/34355-presenting-characteristics-comorbidities-and-outcomes-among-5700-patients-hospitalized-with-covid-19", "https://ichgcp.net/de/clinical-trials-registry/publications/26419-clinical-characteristics-of-113-deceased-patients-with-coronavirus-disease-2019-retrospective-study", "https://pubmed.ncbi.nlm.nih.gov/15659474", "https://ichgcp.net/de/clinical-trials-registry/publications/173030-clinical-features-and-short-term-outcomes-of-102-patients-with-coronavirus-disease-2019-in-wuhan", "https://ichgcp.net/de/clinical-trials-registry/publications/11474-coagulopathy-and-antiphospholipid-antibodies-in-patients-with-covid-19", "https://pubmed.ncbi.nlm.nih.gov/32174129", "https://ichgcp.net/de/clinical-trials-registry/publications/58845-covid-19-and-post-intensive-care-syndrome-a-call-for-action", "https://pubmed.ncbi.nlm.nih.gov/7475776", "https://pubmed.ncbi.nlm.nih.gov/23071307", "https://pubmed.ncbi.nlm.nih.gov/19988326", "https://pubmed.ncbi.nlm.nih.gov/20716675", "https://pubmed.ncbi.nlm.nih.gov/23375475", "https://ichgcp.net/de/clinical-trials-registry/publications/5364-association-of-bcg-dtp-and-measles-containing-vaccines-with-childhood-mortality-systematic-review", "https://pubmed.ncbi.nlm.nih.gov/15652667", "https://ichgcp.net/de/clinical-trials-registry/publications/173031-effects-of-cellular-constituents-of-mycobacteria-on-the-resistance-of-mice-to-heterologous", "https://pubmed.ncbi.nlm.nih.gov/13662534", "https://ichgcp.net/de/clinical-trials-registry/publications/71432-effects-of-bcg-corynebacterium-parvum-and-methanol-extration-residue-in-the-reduction-of-mortality", "https://pubmed.ncbi.nlm.nih.gov/7016070", "https://pubmed.ncbi.nlm.nih.gov/804010", "https://pubmed.ncbi.nlm.nih.gov/808508", "https://ichgcp.net/de/clinical-trials-registry/publications/173032-killing-in-vitro-of-trypanosoma-cruzi-by-macrophages-from-mice-immunized-with-t-cruzi-or-bcg-and", "https://pubmed.ncbi.nlm.nih.gov/659914", "https://ichgcp.net/de/clinical-trials-registry/publications/173033-effect-of-treatment-with-bcg-on-the-course-of-visceral-leishmaniasis-in-balb-c-mice", "https://pubmed.ncbi.nlm.nih.gov/765838", "https://ichgcp.net/de/clinical-trials-registry/publications/173034-molecular-analysis-of-non-specific-protection-against-murine-malaria-induced-by-bcg-vaccination", "https://pubmed.ncbi.nlm.nih.gov/1439583", "https://ichgcp.net/de/clinical-trials-registry/publications/8304-bacille-calmette-guerin-induces-nod2-dependent-nonspecific-protection-from-reinfection-via", "https://pubmed.ncbi.nlm.nih.gov/389657", "https://ichgcp.net/de/clinical-trials-registry/publications/173035-effect-of-mycobacterium-tuberculosis-bcg-infection-on-the-resistance-of-mice-to-ectromelia-virus", "https://ichgcp.net/de/clinical-trials-registry/publications/71433-mechanisms-of-enhanced-resistance-of-mycobacterium-bovis-bcg-treated-mice-to-ectromelia-virus", "https://ichgcp.net/de/clinical-trials-registry/publications/173036-herpesvirus-hominis-type-2-infections-in-rabbits-effect-of-prior-immunization-with-attenuated", "https://pubmed.ncbi.nlm.nih.gov/177992", "https://pubmed.ncbi.nlm.nih.gov/180868", "https://pubmed.ncbi.nlm.nih.gov/894076", "https://ichgcp.net/de/clinical-trials-registry/publications/173037-bacillus-calmette-guerin-induced-trained-immunity-is-not-protective-for-experimental-influenza-a", "https://pubmed.ncbi.nlm.nih.gov/28208151", "https://pubmed.ncbi.nlm.nih.gov/13929573", "https://pubmed.ncbi.nlm.nih.gov/4696469", "https://pubmed.ncbi.nlm.nih.gov/4556666", "https://pubmed.ncbi.nlm.nih.gov/1342506", "https://pubmed.ncbi.nlm.nih.gov/24379224", "https://pubmed.ncbi.nlm.nih.gov/25725054", "https://ichgcp.net/de/clinical-trials-registry/publications/173038-lack-of-bcg-vaccination-and-other-risk-factors-for-bacteraemia-in-severely-malnourished-children", "https://ichgcp.net/de/clinical-trials-registry/publications/173039-risk-factors-for-community-acquired-pneumonia-among-adults-in-kenya-a-case-control-study", "https://pubmed.ncbi.nlm.nih.gov/29635419", "https://pubmed.ncbi.nlm.nih.gov/28338723", "https://pubmed.ncbi.nlm.nih.gov/27429204", "https://ichgcp.net/de/clinical-trials-registry/publications/5367-the-efficacy-of-bacillus-calmette-guerin-vaccinations-for-the-prevention-of-acute-upper-respiratory", "https://ichgcp.net/de/clinical-trials-registry/publications/5366-prevention-of-m-tuberculosis-infection-with-h4-ic31-vaccine-or-bcg-revaccination", "https://pubmed.ncbi.nlm.nih.gov/4364209", "https://pubmed.ncbi.nlm.nih.gov/1523844", "https://ichgcp.net/de/clinical-trials-registry/publications/173040-ineffectiveness-and-toxicity-of-bcg-vaccine-for-the-prevention-of-recurrent-genital-herpes", "https://ichgcp.net/de/clinical-trials-registry/publications/173041-immunotherapy-in-viral-warts-with-intradermal-bacillus-calmette-guerin-vaccine-versus-intradermal", "https://pubmed.ncbi.nlm.nih.gov/26809285", "https://pubmed.ncbi.nlm.nih.gov/22958215", "https://ichgcp.net/de/clinical-trials-registry/publications/5362-bcg-vaccination-protects-against-experimental-viral-infection-in-humans-through-the-induction-of", "https://pubmed.ncbi.nlm.nih.gov/8035041", "https://pubmed.ncbi.nlm.nih.gov/10825039", "https://pubmed.ncbi.nlm.nih.gov/8655980", "https://ichgcp.net/de/clinical-trials-registry/publications/5371-safety-and-reactogenicity-of-bcg-revaccination-with-isoniazid-pretreatment-in-tst-positive-adults", "https://pubmed.ncbi.nlm.nih.gov/6475644", "https://pubmed.ncbi.nlm.nih.gov/3066422", "https://pubmed.ncbi.nlm.nih.gov/29474026", "https://pubmed.ncbi.nlm.nih.gov/6359561", "https://pubmed.ncbi.nlm.nih.gov/10692993", "https://pubmed.ncbi.nlm.nih.gov/19164935", "https://pubmed.ncbi.nlm.nih.gov/10067698", "https://pubmed.ncbi.nlm.nih.gov/13268024", "https://pubmed.ncbi.nlm.nih.gov/6636307", "https://pubmed.ncbi.nlm.nih.gov/17954004", "https://ichgcp.net/de/clinical-trials-registry/publications/173042-genomic-expression-catalogue-of-a-global-collection-of-bcg-vaccine-strains-show-evidence-for-highly", "https://ichgcp.net/de/clinical-trials-registry/publications/173043-early-shared-mycobacterium-bovis-bacillus-calmette-guerin-sub-strains-induce-th1-cytokine-production", "https://pubmed.ncbi.nlm.nih.gov/22071384", "https://pubmed.ncbi.nlm.nih.gov/17558415", "https://pubmed.ncbi.nlm.nih.gov/16425132", "https://ichgcp.net/de/clinical-trials-registry/publications/173044-genome-plasticity-of-bcg-and-impact-on-vaccine-efficacy", "https://pubmed.ncbi.nlm.nih.gov/31677386", "https://pubmed.ncbi.nlm.nih.gov/24336911", "https://ichgcp.net/de/clinical-trials-registry/publications/124839-comparative-tuberculosis-tb-prevention-effectiveness-in-children-of-bacillus-calmette-guerin-bcg", "https://pubmed.ncbi.nlm.nih.gov/18078106", "https://pubmed.ncbi.nlm.nih.gov/19788832", "https://ichgcp.net/de/clinical-trials-registry/publications/173045-efficacy-of-percutaneous-versus-intradermal-bcg-in-the-prevention-of-tuberculosis-in-south-african", "https://pubmed.ncbi.nlm.nih.gov/9987142", "https://ichgcp.net/de/clinical-trials-registry/publications/5373-bcg-vaccine-protection-from-severe-coronavirus-disease-2019-covid-19", "https://ichgcp.net/de/clinical-trials-registry/publications/173046-mandated-bacillus-calmette-guerin-bcg-vaccination-predicts-flattened-curves-for-the-spread-of-covid", "https://ichgcp.net/de/clinical-trials-registry/publications/173047-significantly-improved-covid-19-outcomes-in-countries-with-higher-bcg-vaccination-coverage-a", "https://ichgcp.net/de/clinical-trials-registry/publications/173048-myd88-is-required-for-protection-from-lethal-infection-with-a-mouse-adapted-sars-cov", "https://ichgcp.net/de/clinical-trials-registry/publications/173049-toll-like-receptor-3-signaling-via-trif-contributes-to-a-protective-innate-immune-response-to-severe", "https://ichgcp.net/de/clinical-trials-registry/publications/45303-defining-trained-immunity-and-its-role-in-health-and-disease", "https://ichgcp.net/de/clinical-trials-registry/publications/111926-modulation-of-myelopoiesis-progenitors-is-an-integral-component-of-trained-immunity", "https://coronavirus.jhu.edu/map.html", "https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronavirus%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Nidovirales%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Virus%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pneumonia", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lung%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=COVID-19", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Immunologic%20Factors", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Adjuvants%2C%20Immunologic", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=BCG%20Vaccine", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/de/clinical-trials-registry/NCT06099613", "https://ichgcp.net/de/clinical-trials-registry/NCT06099795", "https://ichgcp.net/de/clinical-trials-registry/NCT06097403", "https://ichgcp.net/de/clinical-trials-registry/NCT06097442", "https://ichgcp.net/de/clinical-trials-registry/NCT06096571", "https://ichgcp.net/de/clinical-trials-registry/NCT06095258", "https://ichgcp.net/de/clinical-trials-registry/NCT06095297", "https://ichgcp.net/de/clinical-trials-registry/NCT06091280", "https://ichgcp.net/de/clinical-trials-registry/NCT06091358", "https://ichgcp.net/de/clinical-trials-registry/NCT06091384", "https://ichgcp.net/de/clinical-trials-registry/NCT05981131", "https://ichgcp.net/de/clinical-trials-registry/NCT05866536", "https://ichgcp.net/de/clinical-trials-registry/NCT05820594", "https://ichgcp.net/de/clinical-trials-registry/NCT05766345", "https://ichgcp.net/de/clinical-trials-registry/NCT05701332", "https://ichgcp.net/de/clinical-trials-registry/NCT05591339", "https://ichgcp.net/de/clinical-trials-registry/NCT05539989", "https://ichgcp.net/de/clinical-trials-registry/NCT05538663", "https://ichgcp.net/de/clinical-trials-registry/NCT05507671", "https://ichgcp.net/de/clinical-trials-registry/NCT05332353", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Middlesex%2BUniversity%2BLondon", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Centre%2Bde%2Bla%2Bmain%2B-%2BCHUV", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Deutsche%2BGesellschaft%2Bf%25C3%25BCr%2BAllgemein-%2Bund%2BViszeralchirurgie", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Nanjing%2BPLA%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Medical%2BSchool%2BBerlin", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Wei%2BZhao", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=LiveRNA%2BTherapeutics%2BInc.", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pirkanmaa%2BHospital%2BDistrict", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Dicle%2BUniversity%2BSchool%2Bof%2BMedicine%252C%2BDiyarbakir%252C%2BTurkey", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Sismanoglio%2B-%2BAmalia%2BFleming%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Tinea%2Bcruris", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Optic%2BNerve", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Dexmedetomidine%252C%2BEsketamine%252C%2BPostoperative%2BPain%2Band%2BRecovery%2BQuality", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Mothers", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Multi-kinase%2BInhibitors", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Musculoskeletal%2BDisorder%2Bof%2Bthe%2BNeck", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Shouldersurgery", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Minimal%2BChange%2BNephropathy", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Intra-ocular%2BPressure", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Invasive%2BDuctal%2BBreast%2BCarcinoma%2BWith%2BPredominant%2BIntraductal%2BComponent", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=CD30.CAR-T", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Ketamine%2Bhigh-dose", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=HM781-36B%2Btablets", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Chinese%2Bherb%2Bmedicine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=0.3%2525%2Bhyaluronic%2Bacid%2Beye%2Bdrops", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=d-amphetamine%2Bsulfate", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Approved%2BICIs", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=FEIBA%2Band%2BNovoSeven", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=bardoxolone%2Bmethyl", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Lyndiol%25C2%25AE", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/cro-list/country/austria", "https://ichgcp.net/de/cro-list/country/bulgaria", "https://ichgcp.net/de/cro-list/country/cameroon", "https://ichgcp.net/de/cro-list/country/canada", "https://ichgcp.net/de/cro-list/country/dr_congo", "https://ichgcp.net/de/cro-list/country/costa_rica", "https://ichgcp.net/de/cro-list/country/finland", "https://ichgcp.net/de/cro-list/country/france", "https://ichgcp.net/de/cro-list/country/hungary", "https://ichgcp.net/de/cro-list/country/italy", "https://ichgcp.net/de/cro-list/country/new_zealand", "https://ichgcp.net/de/cro-list/country/south_korea", "https://ichgcp.net/de/cro-list/country/uzbekistan", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/cro-list/country/papua_new_guinea/company/sgs", "https://ichgcp.net/de/cro-list/country/papua_new_guinea", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/de", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/de/sitemap", "https://ichgcp.net/de/contact-us", "https://ichgcp.net/de/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT04534803", "https://ichgcp.net/de/clinical-trials-registry/NCT04534803", "https://ichgcp.net/clinical-trials-registry/NCT04534803", "https://ichgcp.net/es/clinical-trials-registry/NCT04534803", "https://ichgcp.net/fr/clinical-trials-registry/NCT04534803", "https://ichgcp.net/it/clinical-trials-registry/NCT04534803", "https://ichgcp.net/hu/clinical-trials-registry/NCT04534803", "https://ichgcp.net/nl/clinical-trials-registry/NCT04534803", "https://ichgcp.net/no/clinical-trials-registry/NCT04534803", "https://ichgcp.net/pl/clinical-trials-registry/NCT04534803", "https://ichgcp.net/pt/clinical-trials-registry/NCT04534803", "https://ichgcp.net/fi/clinical-trials-registry/NCT04534803", "https://ichgcp.net/sv/clinical-trials-registry/NCT04534803", "https://ichgcp.net/cs/clinical-trials-registry/NCT04534803", "https://ichgcp.net/ru/clinical-trials-registry/NCT04534803", "https://ichgcp.net/ja/clinical-trials-registry/NCT04534803", "https://ichgcp.net/zh/clinical-trials-registry/NCT04534803", "https://ichgcp.net/ko/clinical-trials-registry/NCT04534803", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}